Acute Coronary Syndrome Care After Discharge – MM1406
GPs are increasingly responsible for treating and managing patients after an acute coronary syndrome (ACS) event. The early recognition of serious complications, and the initiation and maintenance of treatment to increase survival, will improve outcomes among patients with ACS. The judicious use of
appropriate investigations will help guide this care and aid in identifying preventable problems.
Modern Medicine – June 2014
Treating Resistant Hypertension: Now and in the Future – MM1405
Treatment of resistant hypertension is a priority because patients with non-optimal blood pressure are at high risk of major cardiovascular events. Pharmacological advances include use of aldosterone antagonists and the development of several new strategies. Device-based therapies such as catheter-based renal denervation and electrical stimulation of baroreceptors are showing promising results.
Modern Medicine – May 2014
Ambulatory BP Monitoring – MM1310
Hypertension is a major risk factor for cardiovascular (CV) morbidity and mortality.1 Therefore, accurate measurement of blood pressure (BP) is essential to timeously identify individuals at risk and to monitor the efficacy of interventions and treatment adjustments. However, traditional office or clinic BP measurement provides only limited information and may be difficult to interpret, being based on a single or small set of readings dependent on the
technical skills of the clinician.
Modern Medicine – October 2013
Game Changers in Type 2 Diabetes: Microalbuminuria – MM1310
The diabetes complication of microalbuminuria indicates considerable renal damage and an increased risk of cardiovascular events. Its treatment involves improving all aspects of diabetes management and targeting the microalbuminuria itself.
Modern Medicine – October 2013
Unexplained Syncope: 30 Months to Diagnosis Patient Case Study – MM1309
This patient presented to a hospital emergency department following an episode of syncope in June 2009. He was at home, talking on the telephone, when the event occurred. He experienced no lightheadedness or incontinence and described the event as “like how you feel after an amusement park ride”.
Patient was admitted and hospitalised for two days.
Modern Medicine – September 2013
The Practical Value of the Metabolic Syndrome – MM1308
The presence of the metabolic syndrome can be a useful tool to help practitioners identify patients at higher risk for cardiovascular disease and type 2 diabetes. To help reduce such risks, patients with the metabolic syndrome should be targeted with interventions following a multifaceted approach.
Modern Medicine – August 2013
Transient Neurological Troubles in Patients with Type 2 Diabetes – MM1305
Transient neurological attacks, early warning signs of cerebrovascular disease, are usually differentiated by their history. As type 2 diabetes is an important risk factor for a transient ischaemic attack (TIA) and subsequent stroke,
this article focuses on the acute, usually urgent management of this focal transient neurological problem and its prevention.
Modern Medicine – May 2013
Recent Advances in the Treatment of Atrial Fibrillation – MM1304
Atrial fibrillation occurs in paroxysmal, persistent or permanent forms. New anti-arrhythmic agents are being trialed for the pharmacological treatment of affected patients, and catheter ablation is an effective therapeutic intervention for the treatment of patients with symptomatic, drug-refractory paroxysmal atrial fibrillation.
Modern Medicine – April 2013
Patients Post Myocardial Infarction -Tailored Management Improves Outcomes – MM1303
Patients who have had a myocardial infarction need aspirin and statin therapy and careful evaluation to identify those who will benefit from revascularisation  or implantable device therapy and appropriate additional pharmacological treatment.
Modern Medicine – March 2013
Update on Lipid Management – Commonly Asked Questions – MM1302
Target levels for LDL-cholesterol (LDL-C) in patients with cardiovascular
disease (CVD) are being lowered. New statin combinations will
be more cost effective than present combinations and will help to
achieve LDL-C targets. These and other drugs in development promise
a new era in CVD prevention.
Modern Medicine – February 2013
